Shigenori Ohkawa

Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist

Koki Kato, Keisuke Hirai, Keiji Nishiyama et al. · Neuropharmacology · 2004 · 537 citations

Life Sciences, Neuroscience, Pharmacology +12

Novel Inhibitor of p38 MAP Kinase as an Anti-TNF-α Drug:  Discovery of <i>N</i>-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a Potent and Orally Active Anti-Rheumatoid Arthritis Agent

Seiji Miwatashi, Yasuyoshi Arikawa, Etsuo Kotani et al. · Journal of Medicinal Chemistry · 2005 · 145 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Synthesis of a Novel Series of Tricyclic Indan Derivatives as Melatonin Receptor Agonists

Osamu Uchikawa, K. Fukatsu, Ryosuke Tokunoh et al. · Journal of Medicinal Chemistry · 2002 · 136 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acids

Kaneyoshi Kato, Shigenori Ohkawa, Shinji Terao et al. · Journal of Medicinal Chemistry · 1985 · 99 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Ramelteon (TAK-375) Accelerates Reentrainment of Circadian Rhythm after a Phase Advance of the Light-Dark Cycle in Rats

Keisuke Hirai, Muneto Kita, Hiroyuki Ohta et al. · Journal of Biological Rhythms · 2005 · 96 citations

Medicine, Neuroscience, Pharmacology +14